- Home
- EQ vs PLUR Comparison
EQ vs PLUR Comparison
Compare EQ & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQ
- PLUR
- Stock Information
- Founded
- EQ 2017
- PLUR 2001
- Country
- EQ United States
- PLUR Israel
- Employees
- EQ N/A
- PLUR N/A
- Industry
- EQ Biotechnology: Pharmaceutical Preparations
- PLUR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EQ Health Care
- PLUR Health Care
- Exchange
- EQ Nasdaq
- PLUR Nasdaq
- Market Cap
- EQ 24.8M
- PLUR 27.7M
- IPO Year
- EQ 2018
- PLUR N/A
- Fundamental
- Price
- EQ $0.63
- PLUR $4.22
- Analyst Decision
- EQ Buy
- PLUR
- Analyst Count
- EQ 2
- PLUR 0
- Target Price
- EQ $5.00
- PLUR N/A
- AVG Volume (30 Days)
- EQ 130.9K
- PLUR 9.6K
- Earning Date
- EQ 11-13-2024
- PLUR 02-10-2025
- Dividend Yield
- EQ N/A
- PLUR N/A
- EPS Growth
- EQ N/A
- PLUR N/A
- EPS
- EQ N/A
- PLUR N/A
- Revenue
- EQ $45,914,000.00
- PLUR $598,000.00
- Revenue This Year
- EQ $4.76
- PLUR N/A
- Revenue Next Year
- EQ N/A
- PLUR N/A
- P/E Ratio
- EQ N/A
- PLUR N/A
- Revenue Growth
- EQ 7.70
- PLUR 135.43
- 52 Week Low
- EQ $0.49
- PLUR $4.07
- 52 Week High
- EQ $3.25
- PLUR $8.48
- Technical
- Relative Strength Index (RSI)
- EQ 37.33
- PLUR 42.29
- Support Level
- EQ $0.49
- PLUR $4.15
- Resistance Level
- EQ $0.73
- PLUR $4.50
- Average True Range (ATR)
- EQ 0.08
- PLUR 0.19
- MACD
- EQ -0.01
- PLUR 0.01
- Stochastic Oscillator
- EQ 38.92
- PLUR 22.73
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company, that creates cell-based products for commercial use and is pioneering a biotech revolution that promotes wellbeing and sustainability. The company's technology platform developed a three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility. It uses its technology in the field of regenerative medicine, food tech and agricultural technology or agtech.